Therapeutic Patient Education and Cancer Pain
EFFADOL
THERAPEUTIC PATIENT EDUCATION AND CANCER PAIN
1 other identifier
observational
75
1 country
1
Brief Summary
Describe the expectations of therapeutic education for patients in management of cancer pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 12, 2015
CompletedFirst Posted
Study publicly available on registry
March 18, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2016
CompletedMarch 4, 2016
March 1, 2016
1 year
March 12, 2015
March 3, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
describe the expectations of therapeutic education for patients in management of cancer pain
at inclusion
Secondary Outcomes (3)
Describe the expectations of close person in therapeutic education on management of cancer pain
at inclusion
Estimate the intensity of the pain
at inclusion
Estimate the echo of the pain on the daily activity of the patient
at inclusion
Interventions
Eligibility Criteria
Patients with cancer and pain
You may qualify if:
- Patient with cancer diagnosed for at least one month
- Patient with pain from the tumor or its treatment
- Patients with a life expectancy ≥ 6 months
- Health condition compatible with the requirements of the program (WHO performance scale \< or= 2)
- Age over 18 years
- Patient able to understand, speak and read French
- Absence of cognitive impairment
You may not qualify if:
- Primary cancer of the central nervous system or brain metastases
- Disorders of the documented higher functions
- Evolutionary psychiatric pathology
- Drug User
- Abusive alcohol consumption than the WHO recommendations (or 3 glasses of wine per day)
- Refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
centre François Baclesse
Caen, France
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 12, 2015
First Posted
March 18, 2015
Study Start
February 1, 2015
Primary Completion
February 1, 2016
Study Completion
February 1, 2016
Last Updated
March 4, 2016
Record last verified: 2016-03